Oximus Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-12-2024
- Paid Up Capital ₹ 1.00 M
as on 30-12-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
as on 30-12-2024
- Revenue 87.41%
(FY 2022)
- Profit 6995.27%
(FY 2022)
- Ebitda -227.29%
(FY 2022)
- Net Worth 8.08%
(FY 2022)
- Total Assets 60.08%
(FY 2022)
About Oximus Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anil Bansal and Sunita Bansal serve as directors at the Company.
- CIN/LLPIN
U24303DL2017PTC323156
- Company No.
323156
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Oximus Remedies Private Limited offer?
Oximus Remedies Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine.
Who are the key members and board of directors at Oximus Remedies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Bansal  | Director | 04-Sep-2017 | Current |
| Sunita Bansal | Director | 04-Sep-2017 | Current |
Financial Performance of Oximus Remedies.
Oximus Remedies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 87.41% increase. The company also saw a substantial improvement in profitability, with a 6995.27% increase in profit. The company's net worth moved up by a moderate rise of 8.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oximus Remedies?
In 2018, Oximus Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹5.00 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 May 2022 | Hdfc Bank Limited | ₹5.00 M | Satisfied |
How Many Employees Work at Oximus Remedies?
Unlock and access historical data on people associated with Oximus Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oximus Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oximus Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.